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Hantavirus pulmonary syndrome is characterized by vascular permeability, hypoxia, and acute pulmonary edema. Vascular
endothelial growth factor (VEGF) is induced by hypoxia, potently induces vascular permeability, and is associated with high-
altitude-induced pulmonary edema. Hantaviruses alter the normal regulation of β3 integrins that restrict VEGF-directed
permeabilityandhantavirusinfectedendothelial cellsarehyperresponsivetothepermeabilizing eﬀects ofVEGF.However, therole
of VEGF in acute pulmonary edema observed in HPS patients remains unclear. Here we retrospectively evaluate VEGF levels in
pulmonary edema ﬂuid (PEF),plasma, sera, and PBMCs from 31 HPS patients. VEGF was elevated in HPS patients PEF compared
to controls with the highest levels observed in PEF samples from a fatal HPS case. VEGF levels were highest in PBMC samples
during the ﬁrst ﬁve days of hospitalization and diminished during recovery. Signiﬁcantly increased PEF and PBMC VEGF levels
are consistent with acute pulmonary edema observed in HPS patients and HPS disease severity. We observed substantially lower
VEGF levels in a severe HPS disease survivor after extracorporeal membrane oxygenation. These ﬁndings suggest the importance
of patients’ VEGF levels during HPS, support the involvement of VEGF responses in HPS pathogenesis, and suggest targeting
VEGF responses as a potential therapeutic approach.
1.Introduction
Hantavirus Pulmonary Syndrome (HPS) is a hallmark
capillary leak syndrome with a ∼40% mortality rate, and
Sin Nombre (SNV) is a prototypical HPS causing hantavirus
associatedwithoutbreaksofHPSdiseaseintheSouthwestern
United States [1–5]. HPS is characterized by an acute febrile
prodrome with thrombocytopenia rapidly progressing to
acute pulmonary edema, hypoxia respiratory insuﬃciency,
hypotension,andcardiogenicshock[1,2,5–7].Hantaviruses
predominantly infect the endothelial cell lining of vessels
that form the primary ﬂuid barrier of the vasculature. The
pathogenesis of HPS is likely to result from the direct infec-
tion of pulmonary endothelial cells as well as hantavirus-
induced responses of endothelial and immune cells. Immune
cells are hypothesized to contribute to hantavirus disease
through elevated levels of CD8+ T cells and cytokines such
as TNF, yet the vascular endothelium is not disrupted in
patients [5, 8–15]. In vitro SNV-infected endothelial cells
are not permeabilized by infection alone or following the
addition of TNF [14, 16], however pathogenic hantaviruses
bind and inactivate β3 integrins which normally restrict
VEGF-directed capillary permeability [17–21]. This nonlytic
inductionofvascularpermeabilitysuggeststhathantaviruses
alter normal responses of the endothelium to factors that
elicit an edematous disease process [5–7, 10, 14, 16–18, 22–
26].
A suggested role for VEGF in HPS was indicated by
the VEGF enhanced permeability of capillaries within β3
integrin knockout mice [21, 27, 28] and ﬁndings that
pathogenic hantaviruses similarly inhibit β3 integrin func-
tions [17–19, 29]. Subsequent analysis demonstrated that
hantavirus-infected endothelial cells are hyperresponsive to
the permeabilizing eﬀects of VEGF [18, 24, 30, 31]. VEGF is
a cytokine that was ﬁrst identiﬁed as a vascular permeability
factor for its ability to potently induce edema ∼50,0002 Advances in Virology
t i m e sm o r ee ﬀectively than histamine [32]. VEGF is induced
by hypoxic conditions and causes high altitude pulmonary
edema (HAPE) by binding to unique endothelial cell recep-
tors that disrupt adherens junctions [33–39]. VEGF also
transcriptionally induces hypoxia inducible factor-1α (HIF-
1α) forming an autocrine loop that exacerbates permeability
responses during hypoxia [36, 38–40]. The VEGF sensitivity
of SNV infected endothelial cells, the role of VEGF in HAPE,
and ﬁndings that HPS patients are acutely hypoxic prompted
us to retrospectively evaluate VEGF levels in HPS patient
samples.
2. MaterialsandMethods
2.1. HPS Patients. For this study 31 HPS patients between
the ages of 18 and 59 years were referred by their physicians
to the University of New Mexico Health Science Center
between1995and2001fortreatmentofsuspectedhantavirus
infection. Written informed consent was obtained according
to guidelines on human experimentation of the U.S. DHHS,
and the study was approved by the Human Research Review
Committee of the University of New Mexico. Clinical diag-
nosis was provisionally made by peripheral smear criteria
[1] and conﬁrmed by N-protein immunoblot assay [41].
As previously described [42], severe disease (N = 20) was
deﬁned as a requirement for mechanical ventilation (ratio of
partialpressureofarterialoxygen/fractionofinspiredoxygen
<100). Moderately severe disease (N = 2) was deﬁned as
the need for inspired oxygen via continuous positive airway
pressure (CPAP). Mild disease (N = 9) was deﬁned by the
need for oxygen delivered by nasal prongs only or no need
for oxygen administration. Eight subjects with severe disease
developed noncardiogenic shock unrelieved by intravenous
vasopressor therapy and were treated with extracorporeal
membrane oxygenation (ECMO) [43].
2.2. HPS Patient Samples. Venous blood was collected in
EDTA tubes, centrifuged to separate plasma within one
hour of collection, and stored at −80◦C until analysis. Pe-
ripheral blood mononuclear cells (PBMC) were separated
from arterial blood on Ficoll-Hypaque cushions, washed
twice in PBS, and cryopreserved in 20% fetal calf serum,
10% DMSO at −70◦C. Pulmonary edema ﬂuid (PEF) was
collected aseptically by deep aspiration from endotracheal
tubes, centrifuged to remove cellular debris, and stored at
−80◦C. Pulmonary edema ﬂuid (PEF) samples (N = 25)
were collected from three patients, EDTA plasma samples
(N = 56) were received from 31 cases, peripheral blood
mononuclear cell samples (PBMCs) (N = 30) were collected
from the blood of 21 patients and 7 serum samples were
received from 4 patients. PBMCs were archived at 1.0–
2.0 × 107 cells/mL at −80◦C and lysed completely after
a secondary frosting-defrosting procedure. The lysates did
not contain whole PBMC cells and the cells could not be
counted prior to assay [1]. VEGF levels are reported as
pg/107 cells. Control samples used were derived from 13
plasma and sera samples collected from healthy individuals.
Plasma VEGF levels were used as internal controls for PEF
samples and control PBMC samples were collected from 6
healthy persons. All samples were coded and assayed without
knowledge of clinical outcome.
2.3. ELISA Assay. VEGF levels in samples were blindly as-
sessed using a quantitative sandwich ELISA performed with
the Human VEGF ELISA kit (Thermo Scientiﬁc) with a
sensitivity of VEGF detection >8pg/mL. Brieﬂy, VEGF levels
were determined following capture with a solid phase mono-
clonal antibody to VEGF165 IgG and detected using a biotin-
conjugated polyclonal rabbit antibody against recombinant
human VEGF165. The assay was performed according to the
manufacture’s protocol and concentrations are reported as
pg/mL. Data are presented as the results of two independent
blinded ELISAs.
2.4. Statistical Analysis. Results were derived from two
independent blinded experiments and presented as the mean
±SEM with P<0.05 considered signiﬁcant. Multiple
group comparisons were made by one-way ANOVA. Two-
way comparisons were performed by two-tailed, impaired
Student’s t-test. All analysis were performed using GraphPad
Prism software version 5.0.3.
3. Results
3.1. VEGF in Pulmonary Edema Fluid. HPS patient pul-
monary edema ﬂuid (PEF) samples are rare since they
were not routinely stored. However, twenty three serial
samples of pulmonary edema ﬂuid (PEF) were available
from three HPS patients which we retrospectively analyzed
for VEGF levels. HPS Patient 1: four PEF samples were
taken on the ﬁrst day of hospitalization at ∼1 hour intervals
from a patient with severe HPS, who died hours later.
HPS Patient 2: six PEF samples were taken on the ﬁrst
day of hospitalization from a second patient with severe
HPS, who survived after intubation and extracorporeal
membrane oxygenation (ECMO). HPS Patient 3: thirteen
PEF samples were taken on the ﬁrst and second day after
hospitalization from a third patient with moderate-mild
HPS who survived after a brief intubation. We found the
highest PEF VEGF levels (mean 625 ± 95pg/mL) in the
fatal HPS case (Figure 1,T a b l e1), and VEGF levels in
patient 1 were approximately 4-fold higher than in the
ECMO-treated HPS patient (140.8pg/mL). Patient 1 VEGF
levels were 10-fold higher than the VEGF levels of the
HPS patient with moderate-mild disease (mean 60.0pg/mL)
or comparable patient control samples (52.4pg/mL). The
number of PEF samples collected from three patients is a
samplelimitationthatdoesnotallowextrapolatingdatatoall
HPS cases. However, PEF samples from three patients with
diﬀerent HPS manifestations suggest that elevated VEGF
levels correlate with HPS severity.
3.2. Enhanced VEGF Levels in PBMCs. We further studied
PBMC-derived VEGF levels present in twenty-four HPS
patient samples including: 24 with severe HPS, 2 moderate-
severe cases, and 2 mild HPS patients. Mean VEGF levelsAdvances in Virology 3
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Figure 1: VEGF Levels in HPS Patient Pulmonary Edema Fluid. (a) Coded PEF samples from three patients were taken on the ﬁrst and
second days of hospitalization and tested by ELISA. Case 1 samples (N = 4) were taken at ∼1 hour intervals from a patient presenting
with severe HPS who died 6 hours after hospitalization. Case 2 samples (N = 6) were from a patient diagnosed with severe HPS who was
intubated, ECMO-treated, and survived. Case 3 samples (N = 14) were from a patient with moderate HPS who was intubated and survived.
Control VEGF levels are derived from 13 plasma samples from healthy individuals. Results from two independent ELISAs are presented and
expressed as the mean SD. Diﬀerences between VEGF levels from the severe fatal patient were signiﬁcantly diﬀerent from those of severe
ECMO-treated, moderate HPS or controls (P = 0.001) as determined by 1 way ANOVA test. VEGF levels of severe ECMO-treated patients
were not signiﬁcantly diﬀerent from moderate HPS patients (P>0.05), however VEGF levels from severe ECMO-treated patients were
signiﬁcantly diﬀerent from control (P = 0.01). (b) Individual PEF VEGF levels from patients are presented.
Table 1: VEGF level in HCPS patients samples.
Sample n VEGF positive VEGFpg/mL P versus control
Range Mean
PEF
Severe lethal 4 4 340–730 625.0±95.1 <0.001
Severe survival 6 6 105–180 140.8±38.0 <0.01
Moderate severe 14 14 40–110 60.0±5.1 >0.05
Control 13 13 20–80 52.4±6.1
PBMC
Severe 24 23 <8–1,480 465.0±85.7 <0.001
Moderate 2 2 250–400 325.0±75.0 <0.01
Mild 2 2 100–110 105.0±5.0 >0.05
Control 6 6 10–150 61.5±7.4
Plasma
Severe 39 30 10–527 174.4±31.6 <0.01
Mild 17 8 10–310 94.2±23.4 >0.05
Control 13 13 20–80 52.4±6.1
Serum
Severe 3 3 50–60 51.3±3.7 >0.05
Mild 4 2 <8–110 32.5±26.2 >0.05
Control 13 13 22–110 47.2±17.54 Advances in Virology
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Figure 2: PBMC VEGF Levels from HPS Patients. VEGF present in PBMC lysates was measured as in Figure 1. (a) Individual VEGF levels
in PBMCs are presented. Samples from severe cases (N = 24), moderate (N = 2), mild (N = 2), and control (N = 6) were analyzed by
1 way ANOVA. VEGF levels in severe and moderate severe cases were not signiﬁcantly diﬀerent (P>0.05) (see Table 1) and are presented
as one group. PBMC VEGF levels were signiﬁcantly diﬀerent between severe/moderate and mild or control groups (P<0.001). (b) PBMC
VEGF levels from patients with severe (20) HPS are presented (P<0.001) relative to their time of collection (samples collected 1–3 days or
4–17 days after admission). A two-tailed t-test shows signiﬁcantly (P = 0.03) higher VEGF level at early days after hospitalization. (c) Paired
patient PBMC samples from 6 patients with severe HPS were taken during the course of disease and analyzed for VEGF levels. VEGF levels
from samples collected 1–3 days compared to 4–17 days after admission were signiﬁcantly higher at early stages of disease (P = 0.01 using
two-tailed t-test).
in PBMCs from severe, moderate-severe, and mild HPS
patient samples were 465. ± 85.7, 325 ± 075.0, and 105 ±
05.0pg/mL, respectively . Diﬀerences in VEGF levels from
severe and moderate cases versus control are statistically
signiﬁcant, P<0.001 and P<0.01, respectively, while VEGF
levels in mild cases did not diﬀer signiﬁcantly from controls
(P>0.05) (Figure 2(a),T a b l e1). PBMC VEGF levels were
highest during the ﬁrst 3 days of hospitalization (n = 16,
mean526±108.5)comparedtosamplestaken4–17daysafter
admission (n = 11, mean 217 ± 39.6; P = 0.03) and were
found to decrease over time (Figure 2(b)). This observation
was conﬁrmed by VEGF levels in paired samples of 6 HPSAdvances in Virology 5
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Figure 3:PlasmaVEGFLevels ofHPSPatients.(a)PlasmaVEGFlevels wereanalyzed frompatientswith severe(N = 30)formsofHPSasin
Figure 1. Group statistical analysis was made by comparing groups relative to their time of collection (1–5 days compared to 6–10, or 11–20
days) using one-way ANOVA. VEGF levels from samples taken 1–5 days after-admission (N 12; mean 86 ± 34.8mg/mL) were signiﬁcantly
(P<0.05) lower than samples taken 11–20 days (N = 6; mean 262.2 ± 67.5pg/mL) after-admission but not signiﬁcant compared to
samples taken 6–10 days or controls. Diﬀerences in plasma VEGF levels between severe and mild HPS patients were statistically insigniﬁcant
(P>0.05). (b) Paired VEGF levels from 4 HPS patient plasma samples are presented.
patients taken in the same intervals after hospitalization: 1–3
days (n = 6, mean 797.5 ± 200.2) versus 4–17 days (n = 6,
mean 212.3 ±36.9; P = 0.01) (Figure 2(c)).
3.3. VEGF Levels in Plasma and Sera. Serum VEGF levels
were not statistically diﬀerent between controls, mild, or
severe HPS patient samples (3 severe and 4 mild cases)
(P>0.05) (Table 1). In contrast to PEF and PBMC
samples, we found low-plasma VEGF levels in severe HPS
cases during the ﬁrst 3 days of hospitalization (n = 15,
mean 30.4 ± 8.1), and an increase in plasma VEGF levels
during recovery (n = 17, mean 212 ± 49.7; P = 0.001)
(Figures 3(a),a n d3(b);T a b l e1). Plasma VEGF levels were,
respectively, 2 to >3 fold higher in mild and severe HPS
patients than in controls. These results are consistent with
localized rather than systemic permeability responses of
VEGF and ﬁndings that released VEGF reportedly binds
receptors within 0.5mm of its release and is inactivated by
circulating soluble receptors [36, 44].
3.4. VEGF Levels in Parallel Samples. We blindly tested par-
allel samples, but after decoding noticed that a few samples
thatweretakenfromthesamepatients.Intwocases,elevated
VEGF levels were correspondingly observed in PEF and
PBMC samples: severe HPS: 350 and 245pg/mL, respectively
moderate severe case 180 and 90pg/mL; respectively. Addi-
tional positively correlated VEGF ﬁndings were detected in
parallel PBMC and plasma samples from 7 patients (mean
229.2 ±47.1pg/mLand79.3 ±36.9pg/mL;P = 0.03).
4. Discussion
Pulmonary symptoms of HPS patients are characterized by
hypoxia and extensive capillary leakage resulting in acute
bilateral pulmonary edema [2, 5–7, 22, 42, 45]. Hypoxia
induces pulmonary epithelial and endothelial cells to secrete
VEGF [32, 34–37, 39, 40, 46, 47], and VEGF acts on the
endothelium to stimulate growth and dissociate adherence
junctions between endothelial cells [32, 36, 46, 48–51]. This
permits vascular remodeling, vessel repair, and angiogenesis,
but can also locally increase capillary permeability [32, 36,
39, 44, 46, 48, 49, 52]. A VEGF-HIF-1α ampliﬁcation loop
is responsible for high-altitude-induced pulmonary edema,
and over expressing VEGF in the lung causes pulmonary
edema [33–35, 37–40, 52, 53]. Conversely, genetic delivery
of antiVEGF antibody or antagonizing VEGF responses
suppresses pulmonary edema in experimental animals [37,
54–57].
ECMO reduces the progression of respiratory failure and
the mortality of HPS from ∼75% to 35–40% [2, 22, 58]
suggesting a role for hypoxia-induced VEGF in HPS edema
[34, 35, 39, 40, 47, 52, 59]. Pulmonary VEGF is associated
with localized pathogenesis and as a cause of high-altitude
pulmonary edema in response to reduced oxygen levels6 Advances in Virology
[6, 33, 33, 35–37, 39, 40, 47, 52]. Activated pulmonary
PBMCs are increased in HPS patients and PBMCs also
secrete VEGF in response to hypoxia suggesting a potential
mechanism by which localized VEGF immune responses to
hantavirus could contribute to disease [5–7, 60, 61]. Our
ﬁndingsindicatethepresenceofelevatedVEGFinPEFsfrom
severe and moderate HPS cases that are 4–10 fold above
VEGF levels in patients with mild HPS and similar to PEF
VEGF levels from patients with hydrostatic edema (median
799pg/mL) or acute lung injury (median 501pg/mL) [39,
40, 52, 62]. Our ﬁndings also indicate that HPS patient
PBMCs contain high VEGF levels at acute stages 1–5 days
after hospitalization, which diminished over time in paired
patient samples (Figures 2(b),a n d2(c)). Although samples
available were insuﬃcient to analyze viremia here, these
early VEGF responses occur with similar timing to the high-
level viremia previously reported within HPS patients [63].
Collectively,theseﬁndingssuggestthatthereducedmortality
observed following HPS patient oxygenation may be at
least partly derived from inhibiting VEGF/HIF-1α responses
which result in a concomitant reduction in hypoxia-directed
pulmonary edema [34, 35, 37, 40, 47].
VEGF acts within millimeters of its release to prevent
systemic capillary permeability [44], and serum VEGF is
inactivated by binding to circulating soluble receptors [32,
36, 39, 52]. While localized PEF and PBMCs had high VEGF
levels during acute HPS stages we found that circulating
plasma and serum VEGF levels were low in severe HPS
patients during acute HPS stages (1–5 days after hospital-
ization). In contrast, circulating serum and plasma VEGF
levels only increased 11–20 days after-admission (Figures
3(a),a n d3(b)). Increased circulating VEGF at late times
after infection is consistent with vascular remodeling and
repair that occurs during recovery phases of other causes
of acute pulmonary edema and may coincide with HPS
convalescence [32, 33, 36, 39, 44, 46, 48, 49, 52, 64]. These
ﬁndings are similar to studies of patients with high-altitude-
induced pulmonary edema where pulmonary VEGF levels
are associated with acute disease and plasma levels of VEGF
only become elevated during recovery [33]. These ﬁndings
suggest the direct involvement of localized PEF and PBMC
VEGF responses in acuteHPS pathogenesis and the potential
for circulating VEGF to be a sign of patient recovery.
Hantaviruses infect endothelial cells in pulmonary capil-
lary beds [2] and cause hypoxia in HPS patients [2, 5–7, 45].
FindingincreasedVEGFinPEFsandPBMCsfromHPScases
suggests hypoxia-induced pulmonary VEGF induction as a
potential edemagenic mechanism [33, 35, 39, 40, 46, 52].
This data is supported by in vitro results demonstrating that
hantavirus-infected endothelial cells are hyperresponsive
to the permeabilizing eﬀects of VEGF and that blocking
VEGFR2-Src signaling responses inhibits permeability [17,
18, 24, 30]. This mechanism is further linked to the ability
of pathogenic hantaviruses to block αvβ3 integrin functions,
which normally restrict VEGFR2 permeabilizing responses
[18–21, 27, 28]. Thus HPS patient hypoxia in combination
with hantavirus-infected VEGF-hyperresponsive endothelial
cells is likely to contribute to acute pulmonary edema.
Moreover, these results suggest that pathway speciﬁc VEGF
inhibitorsmaybeclinicallyrelevantandusedintandemwith
ECMO to reduce the severity of HPS.
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